Drug intelligence / Profile preview

BI 1815368

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 1815368 is an orally administered small molecule drug candidate developed by Boehringer Ingelheim. Its mechanism of action remains undisclosed or undefined. The compound is a new molecular entity and has not yet received regulatory approval for any indication. As of late 2024, it is in phase I clinical trials, primarily being studied in healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. There are also ongoing studies investigating its interaction with metformin and a planned trial for neovascular age-related macular degeneration[1][2][3][5]. The primary developer and sponsor for all known studies is Boehringer Ingelheim.

Other names: BI 1815368BI1815368BI-1815368

Targets

AOC3 (Amine oxidase copper-containing 3)

Beyond the preview

Go deeper on BI 1815368.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1815368.

Explore the full profile